JASPER THERAPEUTICS INC (JSPR) Forecast, Price Target & Analyst Ratings
NASDAQ:JSPR • US4718712023
1.37 USD
+0.06 (+4.58%)
At close: Mar 10, 2026
1.3935 USD
+0.02 (+1.72%)
After Hours: 3/10/2026, 8:00:03 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for JASPER THERAPEUTICS INC (JSPR).
Forecast Snapshot
Consensus Price Target
$12.92
+ 843.07% Upside
Next Earnings Forecast
Release DateMay 11, 2026
PeriodQ4 / 2025
EPS Estimate-$0.68
Revenue Estimate
ChartMill Buy Consensus
80.00%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$12.92
Upside
+ 843.07%
From current price of $1.37 to mean target of $12.92, Based on 14 analyst forecasts
Low
$4.04
Median
$10.71
High
$26.25
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
14 Wall Street analysts provided a forecast for the next 12 months for JSPR. The average price target is 12.92 USD. This implies a price increase of 843.07% is expected in the next year compared to the current price of 1.37.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
80.00%
JSPR was analyzed by 14 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about JSPR.
In the previous month the buy percentage consensus was at a similar level.
JSPR was analyzed by 14 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-11-11 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2025-09-22 | BTIG | Maintains | Buy -> Buy |
| 2025-09-22 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-09-22 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-08-15 | UBS | Maintains | Buy -> Buy |
| 2025-07-08 | BMO Capital | Downgrade | Outperform -> Market Perform |
| 2025-07-08 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-07-08 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-07-07 | Cantor Fitzgerald | Downgrade | Overweight -> Neutral |
| 2025-07-07 | William Blair | Downgrade | Outperform -> Market Perform |
| 2025-07-07 | BTIG | Maintains | Buy -> Buy |
| 2025-07-07 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-05-15 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-05-13 | UBS | Maintains | Buy -> Buy |
| 2025-03-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-13 | UBS | Initiate | Buy |
| 2025-01-10 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2025-01-10 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-01-09 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-01-06 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2024-12-23 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-12-06 | BMO Capital | Initiate | Outperform |
| 2024-10-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-15 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-10-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateMay 11, 2026
PeriodQ4 / 2025
EPS Estimate-$0.68
Revenue Estimate
Revenue Q2QN/A
EPS Q2Q57.92%
Number of Analysts8
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
JSPR is expected to report earnings on 5/11/2026. The consensus EPS estimate for the next earnings is -0.68 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A -32.59% | N/A 213.92% | N/A 162.83% | N/A 67.93% | |||||||
| EBITDA YoY % growth | N/A | N/A | -36.456M | -50.221M -37.76% | -67.753M -34.91% | -74.866M -10.50% | N/A -28.79% | N/A -25.06% | N/A -17.85% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -4.71M | -20.683M -339.13% | -36.833M -78.08% | -51.196M -38.99% | -68.861M -34.50% | -76.239M -10.71% | N/A -15.49% | N/A -4.33% | N/A -28.01% | N/A -9.13% | N/A 7.56% | N/A -23.19% | N/A 61.10% | N/A 189.14% | N/A 112.58% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -10.30 55.00% | -6.20 39.81% | -4.86 21.61% | N/A 4.98% | N/A 48.63% | N/A 22.47% | N/A 6.47% | N/A 63.54% | N/A -43.09% | N/A 12.50% | N/A 68.83% | N/A 245.83% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.68 57.92% | -0.74 47.70% | -0.75 56.66% | -0.87 30.12% | -0.96 -41.35% | -0.79 -6.50% | -0.77 -1.44% | -0.79 10.08% | -0.80 17.43% |
| Revenue Q2Q % growth | N/A | N/A | N/A | N/A | |||||
| EBITDA Q2Q % growth | -22.981M 3.90% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -18.63M 26.32% | -21.93M -0.59% | -24.888M 8.08% | -28.254M -47.42% | -32.13M -72.47% | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
17.48%
EPS Next 5 Year
13.35%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
-25.25%
EBIT Next 5 Year
N/A
JASPER THERAPEUTICS INC / JSPR Forecast FAQ
What is the price target for JSPR stock?
14 analysts have analysed JSPR and the average price target is 12.92 USD. This implies a price increase of 843.07% is expected in the next year compared to the current price of 1.37.
Can you provide the upcoming earnings date for JASPER THERAPEUTICS INC?
JASPER THERAPEUTICS INC (JSPR) will report earnings on 2026-05-11, before the market open.
Can you provide the consensus estimates for JASPER THERAPEUTICS INC next earnings?
The consensus EPS estimate for the next earnings of JASPER THERAPEUTICS INC (JSPR) is -0.68 USD and the consensus revenue estimate is 0 USD.